Financial & Business News
LATEST INVESTING HEADLINES
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis' new Vice President, Corporate Controller under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awards to individual.
HOUSTON--(BUSINESS WIRE)--ConocoPhillips makes application to cease to be a reporting issuer in Canada.
A relatively little-known information technology executive is running Tesla's sales team as the electric carmaker grapples with a sales freefall, according to people familiar with the matter.
VANCOUVER, British Columbia, July 18, 2025 (GLOBE NEWSWIRE) -- Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) announces that Almaden Minerals Ltd. (“Almaden”) has completed the repayment (“Repayment”) to Almadex of the gold loan pursuant to the secured gold loan agreement, as amended (“Gold Loan”), between Almaden and the Company (see press releases dated June 27, 2024 and May 14, 2019).
NEW YORK , July 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of National Grid plc (NYSE: NGG) resulting from allegations that National Grid plc may have issued materially misleading business information to the investing public. So What: If you purchased National Grid securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.
LOS ANGELES--(BUSINESS WIRE)---- $SRPT--SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Netflix delivered another strong quarter, beating revenue and EPS estimates, driven by a diversified global content slate and robust operating margins. Raised full-year guidance is largely due to FX tailwinds, highlighting the need for the ads business to become the next growth catalyst. Valuation remains attractive with a price target of $1,345, but limited near-term upside and emerging risks warrant a cost-averaging approach.
I expect OptimizeRx to turn profitable in 2025, driven by strong double-digit revenue growth and reduced operating expenses. The company's proprietary AI-powered omnichannel platform connects over 2 million healthcare providers with millions of patients, enabling effective targeted marketing. OPRX's unique Dynamic Audience Activation Platform and Micro-Neighborhood Targeting differentiate it from competitors and support its patient-centered strategy.
David Dietze says "Tesla is going to be tough" when it comes to expecting an earnings beat next week. He points to declining sales and rising EV competition in China as potential headwinds.